GATA Lot to Learn: Decoding the Drivers of Down Syndrome-Associated Acute Leukemias

August 17, 2025
Speakers: Lauren Pommert, MD, MS, Karen Rabin, MD, PhD, Hans Hitzler, MD

In this episode, Contributing Editor, Lauren Pommert, MD, MS, leads a conversation with Karen Rabin, MD, PhD, pediatric oncologist at the University of California, San Francisco, and Hans Hitzler, MD, with SickKids Children's Hospital in Toronto. They discuss advances in understanding the disease biology of down syndrome associated acute leukemia. Support for this episode provided by Autolus.

More Than Medicine: Peer Connection as a Therapeutic Adjunct in Acute Leukemia

July 28, 2025
Speakers: Lori Muffly, MD, MS, Matt, and Rohan

In this episode, Contributing Editor Lori Muffly, MD, MS, leads a conversation with two patients —Matt and Rohan — both of whom have undergone cord blood transplants for their acute myeloid leukemia. They discuss the value of peer connection as a vital component of their leukemia and transplant journey.

Pomalidomide: A Step on the PATH Forward for Treatment of Hereditary Hemorrhagic Telangiectasia

June 23, 2025
Speakers: Surbhi Shah, MBBS, MD, and Keith McCrae, MD

In this episode, Contributing Editor Surbhi Shah, MBBS, MD, a clinician, researcher, and educator at Mayo Clinic in Phoenix, Arizona, talks with Keith McCrae, MD, director of classical hematology at the Taussig Cancer Institute and professor of molecular medicine at the Cleveland Clinic Lerner College of Medicine in Ohio. They discuss a recent paper co-authored by Dr. McCrae, “Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia.” Support for this episode provided byAutolus.

Dual BCR::ABL1 Inhibition Shows Promise in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

May 24, 2025
Speakers: Scott Furlan, MD, Daniel J. DeAngelo, MD, PhD

In this episode, Contributing Editor Scott Furlan, MD, an assistant professor at the Fred Hutch Cancer Center and Department of Pediatrics at the University of Washington in Seattle, talks with Daniel J. DeAngelo, MD, PhD, chief of the leukemia division at the Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School in Boston. They discuss a phase I study with recent results that point to a potentially significant advance in the treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.